Autoimmune Hepatitis
Conditions
Brief summary
Autoimmune hepatitis (AIH) is a progressive inflammatory liver disorder of unknown etiology. If left untreated, it progresses to liver cirrhosis and liver failure. Diagnosis of AIH relies on the exclusion of other causes of liver disease and the presence of positive clinical, biochemical, and histological criteria. AIH has a very wide spectrum of clinical presentations ranging from being asymptomatic to an acute severe fulminant disease. It may be associated with other autoimmune disorders such as thyroiditis, type 1 diabetes, vitiligo, inflammatory bowel disease, or juvenile idiopathic arthritis. Biochemical features of AIH include elevation of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and immunoglobulin G (IgG) in addition to autoantibodies. Liver biopsy is recommended in any patient with suspected autoimmune hepatitis where interface hepatitis is the hallmark of the disease. Immunosuppression is the mainstay of therapy in AIH. Prednisone is administered as the initial therapy either alone or in combination with azathioprine. Liver transplantation is indicated in patients who develop fulminant hepatic failure that is unresponsive to corticosteroids and in patients who develop end-stage liver disease.
Interventions
DIAGNOSTIC_TESTliver biobsy
all pationt will be subjected yo liver biobsy to confirm diagnosis
Sponsors
Sohag University
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Age: under 18 years old. * Both sex. * children suffering from manifestations of Autoimmune Hepatitis. Children previously Diagnosed with Autoimmune Hepatitis
Exclusion criteria
* Patient infected with hepatitis B or C. * Patient had autoimmune hepatitis after liver transplantation. * Patients not respond to steroids and immunosuppressive therapy. Other Causes of acute and chronich hepatitis like wilson disease and Metabolic liver Diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| liver biobsy | 1 year | to confirm charachterstic features of autoimmune hepatitis in liver biobsy as interface hepatitis portal inflammation |
| autoantibody | 1 year | Autoantibodies will be considered positive and clinically significant when present at a dilution ≥1:20 for antinuclear antibody (ANA) and smooth muscle antibody (SMA) or ≥1:10 for liver kidney microsomal (anti-LKM-1). |
Countries
Egypt
Contacts
Primary Contactfathy M abdelhahakam, resident
Backup ContactAshraf M Radwan, assistant professor
Outcome results
None listed